A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: HR+/HER2- Advanced or Metastatic Breast Cancer
Sponsor: Novartis Pharmaceuticals